NCT06219941 2026-02-12
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
Phase 2 Recruiting
Clinical Trials
51 trialsNCT02485834 2025-01-20
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT04770623 2024-01-30
Docetaxel and Irinotecan in Gastric Cancer
Menoufia University
Phase 2 Completed
NCT06197438 2024-01-09
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT00033657 2023-06-28
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT05750290 2023-03-01
CKD-702 Plus Irinotecan in Gastric Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT05025033 2023-01-18
Chemotherapy Combined With Apatinib and PD-1 Antibody
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Completed
NCT05643677 2022-12-09
Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer
Fujian Medical University
Phase 2 Unknown
NCT00911820 2022-11-08
Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT04934618 2021-06-22
A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT04442984 2021-04-13
IRIGA
Blokhin's Russian Cancer Research Center
Phase 2 Unknown
NCT00061932 2021-02-02
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
National Cancer Institute (NCI)
Phase 2 Completed
NCT01084330 2020-12-10
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer
Novartis
Phase 2 Completed
NCT00952003 2020-11-30
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT01928290 2020-08-25
FOLFIRINOX
Washington University School of Medicine
Phase 2 Completed
NCT04358341 2020-08-24
Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Unknown
NCT00003748 2020-08-03
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00020761 2020-08-03
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01498289 2019-11-07
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00183872 2018-02-19
Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
University of Southern California
Phase 2 Completed
NCT03400592 2018-01-17
NIEGA
Peking University
Phase 2 Unknown
NCT00848783 2018-01-08
Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers
NYU Langone Health
Phase 2 Terminated
NCT00201747 2017-12-06
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT02527785 2017-08-23
Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer
Hallym University Medical Center
Phase 2 Completed
NCT00394433 2017-08-01
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00062374 2017-07-06
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
National Cancer Institute (NCI)
Phase 2 Completed
NCT00004235 2016-07-14
Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00737438 2016-02-03
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02662959 2016-01-26
Irinotecan as 3rd Line Therapy in Gastric Cancer
Fudan University
Phase 2 Unknown
NCT00857246 2015-12-07
Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer
NYU Langone Health
Phase 2 Completed
NCT00397904 2015-11-25
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00084617 2015-05-01
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01138904 2014-11-04
FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Advanced Gastric Cancer (AGC)
Dong-A University Hospital
Phase 2 Completed
NCT00991952 2014-05-26
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01444521 2014-05-06
Genotype-drive Study of Irinotecan-Cisplatin Combination for Advanced Gastric Cancer
ChineseAMS
Phase 2 Completed
NCT00005607 2013-12-19
Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01964027 2013-10-17
SIEG
Anhui Medical University
Phase 2 Unknown
NCT00134095 2013-09-17
S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00166881 2013-07-08
P-HDFL-DI
National Taiwan University Hospital
Phase 2 Completed
NCT00003055 2013-06-21
Cisplatin and Irinotecan in Treating Patients With Locally Advanced or Metastatic Esophageal or Gastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00084604 2013-06-04
Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00012363 2012-06-14
S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
SWOG Cancer Research Network
Phase 2 Completed
NCT00215995 2012-01-13
Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00343668 2010-05-26
S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer
Korean Cancer Study Group
Phase 2 Unknown
NCT00447967 2009-09-28
Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric Patients
Hellenic Oncology Research Group
Phase 2 Completed
NCT00512681 2009-09-18
TIROX2
National Cancer Center, Korea
Phase 2 Completed
NCT00165464 2009-04-28
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00675194 2008-05-20
Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer
Johannes Gutenberg University Mainz
Phase 2 Completed
NCT00509964 2007-08-01
Second-Line Irinotecan vs. ILF for AGC
Gachon University Gil Medical Center
Phase 2 Unknown
NCT00320294 2007-03-12
ILF With/Without Cisplatin for Advanced Gastric Cancer
Gachon University Gil Medical Center
Phase 2 Unknown